Early intravenous unfractionated heparin and outcome in acute lung injury and acute respiratory distress syndrome – a retrospective propensity matched cohort study

BMC Pulmonary Medicine

Nicole P Juffermans²  Jan M Binnekade³  Marcus J Schultz²  Marcel Levi¹  Gavin Koh⁵  David J Prins³  Alexander P J Vlaar¹  Jorrit J Hofstra⁴ 

[1] Department Internal Medicine of the Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands;Laboratory for Experimental Intensive Care and Anesthesiology (L.E.I.C.A.), Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands;Department of Intensive Care Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands;Department of Anesthesiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands;Department of Medicine, University of Cambridge, Cambridge, UK

关键词: Critical illness;    Case–control study;    Heparin;    Acute lung injury;   

Others  :  1161076
DOI  :  10.1186/1471-2466-12-43

 received in 2011-12-14, accepted in 2012-07-28,  发布年份 2012

【 摘 要 】

Background

Acute lung injury (ALI) is characterized by a pro-coagulant state. Heparin is an anticoagulant with anti-inflammatory properties. Unfractionated heparin has been found to be protective in experimental models of ALI. We hypothesized that an intravenous therapeutic dose of unfractionated heparin would favorably influence outcome of critically ill patients diagnosed with ALI.

Methods

Patients admitted to the Intensive Care Unit (ICU) of a tertiary referral center in the Netherlands between November 2004 and October 2007 were screened. Patients who developed ALI (consensus definition) were included. In this cohort, the impact of heparin use on mortality was assessed by logistic regression analysis in a propensity matched case–control design.

Results

Of 5,561 admitted patients, 2,138 patients had a length of stay > 48 hours, of whom 723 were diagnosed with ALI (34%), of whom 164 received intravenous heparin. In a propensity score adjusted logistic regression analysis, heparin use did not influence 28-day mortality (odds ratio 1.23 [confidence interval 95% 0.80–1.89], nor did it affect ICU length of stay.

Conclusions

Administration of therapeutic doses of intravenous unfractionated heparin was not associated with reduced mortality in critically ill patients diagnosed with ALI. Heparin treatment did not increase transfusion requirements. These results may help in the design of prospective trials evaluating the use of heparin as adjunctive treatment for ALI.

【 授权许可】

   
2012 Hofstra et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Levi M, Ten CH: Disseminated intravascular coagulation. N Engl J Med 1999, 341:586-592.
• [2]Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS: Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia–a review. Crit Care Med 2006, 34:871-877.
• [3]Dahlem P, Bos AP, Haitsma JJ, Schultz MJ, Meijers JC, Lachmann B: Alveolar fibrinolytic capacity suppressed by injurious mechanical ventilation. Intensive Care Med 2005, 31:724-732.
• [4]Dahlem P, Bos AP, Haitsma JJ, Schultz MJ, Wolthuis EK, Meijers JC, Lachmann B: Mechanical ventilation affects alveolar fibrinolysis in LPS-induced lung injury. Eur Respir J 2006, 28:992-998.
• [5]Choi G, Schultz MJ, Levi M, van der Poll T, Millo JL, Garrard CS: Protein C in pneumonia. Thorax 2005, 60:705-706.
• [6]Ware LB, Fang X, Matthay MA: Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003, 285:L514-L521.
• [7]Welty-Wolf KE, Carraway MS, Ortel TL, Piantadosi CA: Coagulation and inflammation in acute lung injury. Thromb Haemost 2002, 88:17-25.
• [8]Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbruck B, Seeger W: Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000, 161:454-462.
• [9]Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD, National Heart LaBIARDSCTN: Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007, 35:1821-1828.
• [10]Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
• [11]FDA (online source): Xigris [drotrecogin alfa (activated)]: Market Withdrawal - Failure to Show Survival Benefit. 2012.
• [12]Laterre PF, Abraham E, Janes JM, Trzaskoma BL, Correll NL, Booth FV: ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation. Crit Care Med 2007, 35:1457-1463.
• [13]Hofstra JJ, Haitsma JJ, Juffermans NP, Levi M, Schultz MJ: The role of bronchoalveolar hemostasis in the pathogenesis of acute lung injury. Semin Thromb Hemost 2008, 34:475-484.
• [14]Ware LB, Bastarache JA, Wang L: Coagulation and fibrinolysis in human acute lung injury–new therapeutic targets? Keio J Med 2005, 54:142-149.
• [15]Zarychanski R, Doucette S, Fergusson D, Roberts D, Houston DS, Sharma S, Gulati H, Kumar A: Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med 2008, 36:2973-2979.
• [16]Jaimes F, De La Rosa G, Morales C, Fortich F, Arango C, Aguirre D, Muñoz A: Unfractioned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study). Crit Care Med 2009, 37:1185-1196.
• [17]Sebag SC, Bastarache JA, Ware LB: Therapeutic Modulation of Coagulation and Fibrinolysis in Acute Lung Injury and the Acute Respiratory Distress Syndrome. Curr Pharm Biotechnol 2011, 12:1481-1496.
• [18]Ware LB, Camerer E, Welty-Wolf K, Schultz MJ, Matthay MA: Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2006, 291:L307-L311.
• [19]Hofstra JJ, Juffermans NP, Schultz MJ, Zweers MM: Pulmonary coagulopathy as a new target in lung injury–a review of available pre-clinical models. Curr Med Chem 2008, 15:588-595.
• [20]Lantz M, Thysell H, Nilsson E, Olsson I: On the binding of Tumor Necrosis Factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest 1991, 88:2026-2031.
• [21]Lever R, Hoult JR, Page CP: The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro. Br J Pharmacol 2000, 129:533-540.
• [22]Pernerstorfer T, Hollenstein U, Hansen J, Knechtelsdorfer M, Stohlawetz P, Graninger W, Eichler HG, Speiser W, Jilma B: Heparin blunts endotoxin-induced coagulation activation. Circulation 1999, 100:2485-2490.
• [23]Darien BJ, Fareed J, Centgraf KS, Hart AP, MacWilliams PS, Clayton MK, Wolf H, Kruse-Elliott KT: Low molecular weight heparin prevents the pulmonary hemodynamic and pathomorphologic effects of endotoxin in a porcine acute lung injury model. Shock 1998, 9:274-281.
• [24]Slofstra SH, van’t Veer C, Buurman WA, Reitsma PH, ten Cate H, Spek CA: Low molecular weight heparin attenuates multiple organ failure in a murine model of disseminated intravascular coagulation. Crit Care Med 2005, 33:1365-1370.
• [25]Cox CS Jr, Zwischenberger JB, Traber DL, Traber LD, Haque AK, Herndon DN: Heparin improves oxygenation and minimizes barotrauma after severe smoke inhalation in an ovine model. Surg Gynecol Obstet 1993, 176:339-349.
• [26]Mu E, Ding R, An X, Li X, Chen S, Ma X: Heparin attenuates lipopolysaccharide-induced acute lung injury by inhibiting nitric oxide synthase and TGF-beta/Smad signaling pathway. Thromb Res 2012, 129:479-485.
• [27]Li LF, Yang CT, Huang CC, Liu YY, Kao KC, Lin HC: Low-molecular-weight heparin reduces hyperoxia-augmented ventilator-induced lung injury via serine/threonine kinase-protein kinase B. Respir Res 2011, 12:90. BioMed Central Full Text
• [28]Dixon B, Schultz MJ, Hofstra JJ, Campbell DJ, Santamaria JD: Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. Crit Care 2010, 14:445. BioMed Central Full Text
• [29]Vlaar AP, Binnekade JM, Prins D, van Stein D, Hofstra JJ, Schultz MJ, Juffermans NP: Risk factors and outcome of transfusion-related acute lung injury in the critically ill: a nested case–control study. Crit Care Med 2010, 38:771-778.
• [30]Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, LeGall JR, Morris A, Spragg R: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994, 149:818-824.
• [31]Gajic O, Gropper MA, Hubmayr RD: Pulmonary edema after transfusion: how to differentiate transfusion-associated circulatory overload from transfusion-related acute lung injury. Crit Care Med 2006, 34:S109-S113.
• [32]The Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000, 342:1301-1308.
• [33]Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, Connors AF Jr, Hite RD, Harabin AL: Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006, 354:2564-2575.
• [34]Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, Tolley EA: Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 1998, 280:159-165.
• [35]Glynn RJ, Schneeweiss S, Sturmer T: Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006, 98:253-259.
• [36]Luellen JK, Shadish WR, Clark MH: Propensity scores: an introduction and experimental test. Eval Rev 2005, 29:530-558.
• [37]Abubakar K, Schmidt B, Monkman S, Webber C, DeSA D, Roberts R: Heparin improves gas exchange during experimental acute lung injury in newborn piglets. Am J Respir Crit Care Med 1998, 158:1620-1625.
• [38]Murakami K, McGuire R, Cox RA, Jodoin JM, Bjertnaes LJ, Katahira J, Traber LD, Schmalstieg FC, Hawkins HK, Herndon DN, et al.: Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock 2002, 18:236-241.
• [39]Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ: Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care 2010, 14:R180. BioMed Central Full Text
• [40]Iba T, Kidokoro A, Fukunaga M, Nagakari K, Suda M, Yoshikawa S, Ida Y: Antithrombin ameliorates endotoxin-induced organ dysfunction more efficiently when combined with danaparoid sodium than with unfractionated heparin. Intensive Care Med 2005, 31:1101-1108.
• [41]Murakami K, Enkhbaatar P, Shimoda K, Mizutani A, Cox RA, Schmalstieg FC, Jodoin JM, Hawkins HK, Traber LD, Traber DL: High-dose heparin fails to improve acute lung injury following smoke inhalation in sheep. Clin Sci (Lond) 2003, 104:349-356.